Mechanism of action and pharmacokinetics
Like other lincosamides, clindamycin inhibits protein synthesis at the translocation stage by blocking peptide bond formation. The main target is the 50S ribosomal subunit, which determines its similarity to macrolides. The drug predominantly exhibits a bacteriostatic type of action, although in high concentrations it can exert a bactericidal effect.
Compared to lincomycin, clindamycin has a number of pharmacokinetic advantages: its bioavailability reaches ~90%, and the absorption process in the gastrointestinal tract is independent of food intake. The duration of action of the drug is about 6 hours. A characteristic feature of the entire group is the ability to accumulate in bone tissue and joints.
Pharmacological effects and spectrum of activity
The spectrum of antimicrobial activity of clindamycin covers:
- Gram-positive cocci: staphylococci (including penicillinase-producing strains), streptococci, and pneumococci.
- Gram-positive bacilli: diphtheria pathogen.
- Anaerobes: causative agents of gas gangrene, tetanus (Clostridium perfringens, Clostridium tetani), and severe infections caused by Bacteroides fragilis.
- Protozoal infections: high activity against the causative agents of Pneumocystis pneumonia, toxoplasmosis, and malaria plasmodia (in high doses).
Cross-resistance to the drug is associated with the MLS phenotype: constitutive production of methylase enzymes (modification of the target—ribosomes) causes simultaneous resistance to macrolides, lincosamides, and group B streptogramins.
Main indications for use
Clindamycin is a drug of choice or an important component of combination therapy for the following conditions:
- Anaerobic and mixed infections: severe pathologies caused by bacteroides and associations of other anaerobes.
- Tropcial malaria: used in a combination regimen with quinine for chloroquine-resistant forms (Plasmodium falciparum), acting on the erythrocytic stage.
- Toxoplasmosis: used as an alternative treatment regimen in combination with pyrimethamine (in case of sulfonamide intolerance).
- Bone and joint infections: due to its property of depositing in bones.
Side effects and resistance features
The main problem with the use of clindamycin is the risk of developing antibiotic-associated conditions caused by the suppression of normal intestinal microflora. Mechanisms of bacterial resistance to the drug include:
- Target modification: methylation of the ribosomal binding site using methylase enzymes (the main pathway in gram-positive microorganisms).
- Enzymatic inactivation: formation of esterases that hydrolyze the drug structure.
- Transport impairment: decreased membrane permeability and active efflux (efflux).
Administration and dosing details
The drug is available in various dosage forms for differentiated use:
- Capsules 0.15 and 0.3 g.
- Syrup in 80 ml bottles (0.075 g in 5 ml).
- Solution for injection in 15% ampoules — 2 and 4 ml.
- Vaginal cream (0.1 g of drug per 1 g).
Dosage regimen: Administered orally in doses of 0.15–0.6 g. Intramuscularly administered at 0.3 g 2 times a day. For severe infections, intravenous drip administration is indicated in a daily dose of up to 1.2–4.8 g (divided into 2–4 administrations).
Briefly: answers to topical questions
What specific severe intestinal complication does clindamycin cause?
The use of lincosamides, particularly clindamycin, is most commonly associated with the development of pseudomembranous colitis. This condition is a type of superinfection characterized by the uncontrolled proliferation of the bacterium Clostridium difficile, which is a component of the normal microflora, against the background of the suppression of other microorganisms by the antibiotic. The pathogen produces an enterotoxic cytotoxin that leads to mucosal ulceration, fever, and severe diarrhea, sometimes mixed with blood.
ClindaMycin — Target of Macrolides (50S subunit) and Methylase Modification.
Class and exam questions
What is the main pharmacokinetic advantage of clindamycin over lincomycin?
Clindamycin has a higher bioavailability (about 90%), and unlike lincomycin, its absorption in the gastrointestinal tract does not depend on food intake.
What is the target and mechanism of action of clindamycin at the microbial cell level?
The drug inhibits protein synthesis at the translocation stage by reversibly binding to the 50S subunit of the bacterial ribosome.
What drugs is clindamycin combined with to treat tropical malaria and toxoplasmosis?
In falciparum malaria (chloroquine-resistant forms), clindamycin is combined with quinine, and in toxoplasmosis with pyrimethamine.
What is the MLS resistance phenotype?
This is cross-resistance, in which the production of methylase enzymes by bacteria leads to simultaneous resistance to macrolides, lincosamides, and streptogramins.
What else to study on this topic
- Comparative pharmacokinetics of lincomycin and clindamycin
- Molecular basis of the MLS phenotype and the role of methylases
- Spectrum of antibacterial activity against anaerobes (Bacteroides fragilis)
- Combination therapy for chloroquine-resistant malaria
- Features of lincosamide accumulation in bone tissue during osteomyelitis
- Alternative pharmacotherapy regimens for toxoplasmosis involving lincosamides
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Clindamycin" and 5,304 more subject pages
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the «Drugs and Prescriptions» section
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.